anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: Multiple studies have shown a low risk of ipsilateral breast events (IBEs) or other recurrences for selected patients age 65-70 years or older with stage I breast cancers treated with breast-conserving surgery (BCS) and endocrine therapy (ET) without adjuvant radiotherapy. We sought to evaluate whether younger postmenopausal patients could also be successfully treated without radiation therapy, adding a genomic assay to classic selection factors.
METHODS: Postmenopausal patients age 50-69 years with pT1N0 unifocal invasive breast cancer with margins ≥2 mm after BCS whose tumors were estrogen receptor-positive, progesterone receptor-positive, and human epidermal growth factor receptor 2-negative with Oncotype DX 21-gene recurrence score ≤18 were prospectively enrolled in a single-arm trial of radiotherapy omission if they consented to take at least 5 years of ET. The primary end point was the rate of locoregional recurrence 5 years after BCS.
RESULTS: Between June 2015 and October 2018, 200 eligible patients were enrolled. Among the 186 patients with clinical follow-up of at least 56 months, overall and breast cancer-specific survival rates at 5 years were both 100%. The 5-year freedom from any recurrence was 99% (95% CI, 96 to 100). Crude rates of IBEs for the entire follow-up period for patients age 50-59 years and age 60-69 years were 3.3% (2/60) and 3.6% (5/140), respectively; crude rates of overall recurrence were 5.0% (3/60) and 3.6% (5/140), respectively.
CONCLUSION: This trial achieved a very low risk of recurrence using a genomic assay in combination with classic clinical and biologic features for treatment selection, including postmenopausal patients younger than 60 years. Long-term follow-up of this trial and others will help determine whether the option of avoiding initial radiotherapy can be offered to a broader group of women than current guidelines recommend.
OBJECTIVES: To assess the efficacy of a single intradiscal injection of allogeneic bone marrow mesenchymal stromal cells (BM-MSCs) versus a sham placebo in patients with chronic low back pain (LBP).
METHODS: Participants were randomised in a prospective, double-blind, controlled study to receive either sham injection or intradiscal injection of 20 million allogeneic BM-MSC, between April 2018 and December 2022. The first co-primary endpoint was the rate of responders defined by improvement of the Visual Analogue Scale (VAS) for pain of at least 20% and 20 mm, or improvement of the Oswestry Disability Index (ODI) of 20% between baseline and month 12. The secondary structural co-primary endpoint was assessed by the disc fluid content measured by quantitative MRI T2, between baseline and month 12. Secondary endpoints included pain VAS, ODI, the Short Form (SF)-36 and the minimal clinically important difference in all timepoints (1, 3, 6, 12 and 24 months). We determined the immune response associated with allogeneic cell injection between baseline and 6 months. Serious adverse events (SAEs) were recorded.
RESULTS: 114 patients were randomised (n=58, BM-MSC group; n=56, sham placebo group). At 12 months, the primary outcome was not reached (74% in the BM-MSC group vs 69% in the placebo group; p=0.77). The groups did not differ in all secondary outcomes. No SAE related to the intervention occurred.
CONCLUSIONS: While our study did not conclusively demonstrate the efficacy of allogeneic BM-MSCs for LBP, the procedure was safe. Long-term outcomes of MSC therapy for LBP are still being studied.
TRIAL REGISTRATION NUMBER: EudraCT 2017-002092-25/ClinicalTrials.gov: NCT03737461.
BACKGROUND: Heart failure is a serious chronic medical condition that negatively impacts daily living. Living with heart failure can be challenging due to the physical symptoms, unpredictable nature of the disease, and lifestyle changes required. The objective of this study was to explore and describe the experiences of people living with heart failure and how it affects their health-related quality of life in Ethiopia.
METHODS: A qualitative descriptive design was employed to explore the experience of people living with heart failure, guided by the Theory of Symptom Management. A purposive sample of 14 participants was recruited from the cardiac outpatient clinics at two tertiary-level public hospitals in Ethiopia. Data were collected using a semi-structured interview. The recorded interviews were transcribed verbatim in Amharic, translated into English, and entered NVivo statistical software for analysis. An inductive-deductive hybrid thematic analysis method was used to analyse the data.
RESULTS: Three themes were identified deductively, while an additional three themes emerged inductively:-"Journey from diagnosis to daily life with heart failure"; "Symptom experience"; "Impact of heart failure on health-related quality of life"; "Perception of health-related quality of life and influencing factors"; "Symptom management and coping strategies"; and "Challenges faced in the journey of living with heart failure". Fatigue, and depression were the most frequently reported symptoms. Participants described how their condition affected their overall physical functioning. Participants utilized consistent follow up-care, adhered to their medications, ensured adequate rest, made dietary modifications, sought social support and engaged in spiritual activities to manage their symptoms and cope with their condition. Challenges they faced included financial difficulties, unavailability of medications, and a lack of continuity of care.
CONCLUSION: People living with heart failure in Ethiopia experience various symptoms. The impact of heart failure on various aspects of their lives, combined with the challenges they face while living with heart failure, significantly affect their health-related quality of life. Health care providers caring for these people need to understand their experiences and the impact on their daily life. Effective multimodal interventions are needed to reduce the impact of heart failure and improve health-related quality of life in this population.
Radiation therapy is a critical modality for treatment of urologic, gynecologic and gastrointestinal malignancies among others. Though advances in treatment techniques have reduced treatment-associated morbidity and mortality, normal tissue toxicity still limits dose escalation and treatment tolerance. Over 50% of patients receiving abdominal or pelvic radiation therapy (RT) develop clinically meaningful toxicity. Pharmacologic strategies to reduce normal tissue damage represent a tremendous unmet need in RT. Investigators propose a novel application of short chain fatty acids (SCFA) as a therapeutic to reduce incidence and severity of gastrointestinal (GI) toxicity from RT. Short chain fatty acids (SCFA) are fatty acids with fewer than six carbon atoms ingested or formed during bacterial fermentation of partially- and non-digestible polysaccharides carbohydrates. Patients who are enrolled will be randomized to receive SCFA supplements or a placebo, and will start taking it everyday one week prior to starting RT through 1 week after completing RT. Patients will keep a log of daily administration during the entire time while taking the study drug, and will complete patient reported outcomes (PROs) involving toxicities starting at baseline through 3 months post RT. The patient's treating physician will also complete an assessment of the patients toxicities starting at the baseline through follow up visits up to 5 years post RT, which will be used to compare to the PROs.
The term "Fusarium Head Blight" (FHB) resistance supposedly covers common resistances to different Fusarium spp. without any generally accepted evidence. For food safety, all should be considered with their toxins, except for deoxynivalenol (DON). Disease index (DI), scabby kernels (FDK), and DON steadily result from FHB, and even the genetic regulation of Fusarium spp. may differ; therefore, multitoxin contamination is common. The resistance types of FHB form a rather complex syndrome that has been the subject of debate for decades. It seems that resistance types are not independent variables but rather a series of components that follow disease and epidemic development; their genetic regulation may differ. Spraying inoculation (Type 1 resistance) includes the phase where spores land on palea and lemma and spread to the ovarium and also includes the spread-inhibiting resistance factor; therefore, it provides the overall resistance that is needed. A significant part of Type 1-resistant QTLs could, therefore, be Type 2, requiring the retesting of the QTLs; this is, at least, the case for the most effective ones. The updated resistance components are as follows: Component 1 is overall resistance, as discussed above; Component 2 includes spreading from the ovarium through the head, which is a part of Component 1; Component 3 includes factors from grain development to ripening (FDK); Component 4 includes factors influencing DON contamination, decrease, overproduction, and relative toxin resistance; and for Component 5, the tolerance has a low significance without new results. Independent QTLs with different functions can be identified for one or more traits. Resistance to different Fusarium spp. seems to be connected; it is species non-specific, but further research is necessary. Their toxin relations are unknown. DI, FDK, and DON should be checked as they serve as the basic data for the risk analysis of cultivars. A better understanding of the multitoxin risk is needed regarding resistance to the main Fusarium spp.; therefore, an updated testing methodology is suggested. This will provide more precise data for research, genetics, and variety registration. In winter and spring wheat, the existing resistance level is very high, close to Sumai 3, and provides much greater food safety combined with sophisticated fungicide preventive control and other practices in commercial production.
There will be 5 sequential cohorts (Groups A-E) with 3 subjects in each cohort. Each cohort will follow a dose escalation plan. New patients will be enrolled into each group. No control group is included. All patients will received spinal cord injections of HSSC.
Gout is characterized by monosodium urate (MSU) crystal deposition secondary to hyperuricemia. Gout is associated with metabolic syndrome (MetS) and its related comorbid conditions such as cardiovascular disease (CVD). Major advances have been made in the comprehension of the link between MetS and gout. Despite observational studies suggesting an association between MetS-related conditions and hyperuricemia, there is no proof of causality. Most studies using Mendelian randomization did not find hyperuricemia as a causal factor for MetS-related conditions. In contrast, these conditions were found associated with hyperuricemia, which suggests a reverse causality. Among patients with gout, this high CVD risk profile implies the need for systematic screening for MetS-related conditions. Most international guidelines recommend systematic screening for and care of CVD and related risk factors in patients with gout. Some anti-hypertensive agents, such as losartan and calcium channel blockers, are able to decrease serum urate (SU) levels. However, there are potential interactions between gout management therapies and the treatment of metabolic diseases. Some data suggest that anti-inflammatory drugs used for gout flare treatment, such as colchicine or canakinumab, might have benefits for CVD. Regarding the impact of urate-lowering therapies on CVD risk, recent studies found a similar CVD safety profile for allopurinol and febuxostat. Finally, sodium-glucose cotransporter-2 inhibitors are promising for gout because of their ability to decrease SU levels and risk of recurrent flares. In this review, we focus on the clinical challenge of managing MetS in patients with gout, particularly older patients with co-medications.
Transcriptomic analyses have advanced the understanding of complex disease pathophysiology including chronic obstructive pulmonary disease (COPD). However, identifying relevant biologic causative factors has been limited by the integration of high dimensionality data. COPD is characterized by lung destruction and inflammation, with smoke exposure being a major risk factor. To define previously unknown biological mechanisms in COPD, we utilized unsupervised and supervised interpretable machine learning analyses of single-cell RNA-Seq data from the mouse smoke-exposure model to identify significant latent factors (context-specific coexpression modules) impacting pathophysiology. The machine learning transcriptomic signatures coupled to protein networks uncovered a reduction in network complexity and new biological alterations in actin-associated gelsolin (GSN), which was transcriptionally linked to disease state. GSN was altered in airway epithelial cells in the mouse model and in human COPD. GSN was increased in plasma from patients with COPD, and smoke exposure resulted in enhanced GSN release from airway cells from patients with COPD. This method provides insights into rewiring of transcriptional networks that are associated with COPD pathogenesis and provides a translational analytical platform for other diseases.
Many skin care products contain heavy metals and certain harmful additives, and can cause damages to human bodies when used for a long time. A special skin care product is very high in price, and most people cannot afford the consumption. The invention discloses a preparation method of a honey-mulberry fruit lotion, and by adopting the preparation method, a skin care product is prepared from honey mulberry fruits and glycerol which are easy to obtain. The skin care product does not contain harmful heavy metals, and also does not contain additives unfavorable for the human bodies. Moreover, the price of the skin care product is relatively low, and the preparation method is easy to grasp. The lotion not only can moisten skins, but also can be used for preventing sunburn, resisting wrinkles, moisturizing and removing dead skins on faces, and also can be used for preventing lips and hand back from seasoning crack in winter.
The invention relates to the field of medicinal preparations and particularly relates to a montelukast sodium chewable tablet, apreparation method and a determination method of a dissolution rate. Raw materials of the montelukast sodium chewable tablet comprise montelukast sodium, mannitol, microcrystalline cellulose, hydroxy propyl cellulose, crosslinking sodium carboxymethylcellulose, aspartame, ferric oxide, magnesium stearate and cherry essence. The hydroxy propyl cellulose is prepared into a solution with a mass percentage content being 6-8% through water being a solvent and a disintegrating agent is prepared through a wet process of an internal addition method. The montelukast sodium chewable tablet is significantly increased in disintegrating speed and in-vitro dissolution rate. By means of a dissolution curve detection method, quality differences among products in each batch can be effectively distinguished. Differences between products in each batch can be reduced better and a quality risk of the products can be controlled in a controllable range.
The invention relates to a brain strengthening powder, belongs to a Chinese patent medicine, and in particular relates to a Chinese patent medicine used for treating cerebral concussion sequelae. The invention aims at developing a traditional Chinese medicine capsule which is in accordance with the theory of traditional Chinese medicine, can be used for treating the cerebral concussion sequelae by pure natural formulation, is remarkable in treatment effect, less in side effect, wide in medicine source and simple in technology, can be produced on a large scale, and meets the demands of patients. The technical scheme of the invention is as follows: the brain strengthening powder comprises the medicines by weight percent: 15% of red ginseng, 10% of Chinese polyphaga, 10% of Chinese angelica, 5% of the fruit of Chinese wolfberry, 5% of prepared nux vomica, 10% of whole dragon, 15% of human placenta, 15% of ligusticum wallichii, 5% of endothelium corneum gigeriae galli and 10% of lumbricus. The brain strengthening powder is prepared by evenly stirring and mixing the ten medicines and carrying out ultrafine grinding to prepare powder. About 5g of the powder is taken after being mixed with water after meal for three times every day, the brain strengthening powder generally takes effect after 1-2 weeks, and then the brain strengthening powder is continuously taken for 2-3 months. The brain strengthening powder can basically cure the cerebral concussion sequelae, and is also used for serious psychoneurosis patients.
The invention relates to a traditional Chinese medicine composition for treating syndromes of deficient cold of spleen and stomach and a preparation method of the traditional Chinese medicine composition, belonging to the technical field of medicine preparation. The traditional Chinese medicine composition is mainly technically characterized by comprising the following traditional Chinese medicine raw materials: 3-4 parts of dried tangerine or orange peel, 2-3 parts of elecampane, 9-12 parts of folium artemisiae argyi, 3-4 parts of clove, 3-4 parts of cinnamon, 2-3 parts of rhizoma zingiberis, 1-2 parts of corydalis tuber, 2-3 parts of fennel, 1-2 parts of rhizoma atractylodis, 2-3 parts of fructus evodiae, 2-3 parts of Angelica sinensis, 1-2 parts of radix bupleuri, 1-2 parts of fructus cnidii, 1-2 parts of the root of straight ladybell and 3-4 parts of honey-fried licorice root. The traditional Chinese medicine composition is prepared by the steps: cleaning and preparing, mixing and grinding, sterilizing, thereby obtaining the product. The composition disclosed by the invention is strict in compatibility, reasonable in matching and simple in preparation method. The experiment proves that the composition disclosed by the invention has obvious effects of protecting acute and chronic gastric mucosal damage, is capable of improving the hemorheology and has the effects of tonifying spleen, promoting blood circulation to remove blood stasis and obviously relieving pain. The traditional Chinese medicine composition can be used for diseases such as swelling pain of stomach duct and abdomen, crymodynia, reduced appetite and loose stool caused by deficiency-cold in spleen and stomach, cold coagulation and middle burner and Qi-stagnation and blood stasis.
After 30 min after initiation of nitric oxide therapy following randomization, once patient stability has been confirmed, a brief recruitment maneuver will be performed and the subsequent PEEP level will be individualized according to the best lung compliance. Ventilation will then continue with the standard baseline ventilator settings, but with the PEEP level individually optimized.
PURPOSE:To decrease as less as possible the waiting time of the patients by using a window processor, a clinical chart retriever, a consultation room processor and a patient calling device, etc. to process a consultation ticket made of a visible magnetic card. CONSTITUTION:When a consultation ticket Cd made of a magnetic card of a non-fist visit patient is put into a window processor A, the position of a medical chart is shown automatically by a clinical chart retriever B based on the data read out of the ticket Cd. Then the ticket Cd is accepted and this acceptance number is set automatically. This acceptance number is displayed visibly at a display part of the ticket Cd. Then a calling counter is advanced by a consultation room processor when the consultation is through. The acceptance number is displayed at the number display part of a patient calling device D. Thus the waiting patient can collate the number shown on his/her ticket Cd with the number displayed on the device D.
The QL 2 block is a novel fascial plane block recently described by Blanco and colleagues in which local anesthetic is deposited adjacent to the antero-lateral aspect of the quadratus lumborum muscle. This results in posterior spread of local anesthetic through the middle layer of the thoraco-lumbar fascia, which theoretically communicates with the paravertebral space resulting in potentially longer-lasting and denser analgesia than wound infiltration. Like the more commonly used transversus abdominis plane (TAP) block, the QL 2 block targets the anterior rami of T7-T12, ilioinguinal, iliohypogastric, and the lateral cutaneous branches of L1-L3. The QL 2 block derives from the TAP block, which is also a fascial plane block that is commonly used to treat pain following surgery involving the anterior abdominal wall. However, the QL block's more posterior location has recently been shown to provide a longer lasting and more profound analgesic effect than the TAP block, possibly by communicating with the paravertebral space. Although the TAP has been shown to be effective in a variety of surgical procedures involving an anterior abdominal wall incision including laparoscopic bariatric surgery the QL 2 block has until now, not been studied in the context of bariatric surgery. Conventional therapy has consisted of surgical infiltration of the incision ports with bupivacaine 0.25%. The study team proposes a study to compare the analgesic effects of the QL 2 block with conventional therapy, consisting of surgical wound infiltration, for postoperative analgesia following laparoscopic gastric sleeve gastrectomy.
PURPOSE:To obtain a carcinostatic agent extremely effectively used as an antitumor agent or a carcinostatic agent for treating cancer due to its excellent carcinostatic activity, low toxicity with hardly any side effects such as decrease in body weight, etc., and pharmacologically improved characteristics. CONSTITUTION:A carcinostatic agent containing a perfluoro-1-methyl-2-oxapentyl group-containing uracil derivative expressed by formula I (R is H or 1-4C alkyl), e.g. 5-(perfluoro-1-methyl-2-oxapentyl)-1,3-dimethyluracil expressed by formula II as an active ingredient. The above-mentioned carcinostatic agent is capable of exhibiting powerful proliferation inhibitory effects on cancerous cells. Furthermore, the above-mentioned compound can orally or parenterally such as intrarectally, subcutaneously, intramuscularly or intravenously be administered and the dose is normally 1-1000mug/kg-body weight/day in one or several portions, e.g. 2 to 6 divided portions a day. The compound can be obtained by reacting perfluoro-2-methyl-3-oxahexanoyl peroxide with uracils.
Face packs consist of cellulose, agar-agar, gelose or other seaweed extracts and vegetable oils. They pref. also contain hydrolysates of fresh or dry vegetables or fruits and vegetable or fruit extracts to which are attached trace elements or aldehyde-gp. contg. sugars. The packs do not dry rapidly on the skin and the feeling of constriction is avoided. Sterilised cellulose powder is added to vegetable extracts and vegetable or fruit juice. The compsn. is then re-sterilised either in an autoclave or in a dessicator at 120 degrees C.